Loading organizations...
§ Private Profile · Liège, Liege, Belgium
Clinical-stage biopharmaceutical company developing active specific immunotherapies for severe chronic autoimmune diseases, including type 1 diabetes.
Imcyse is a clinical-stage biopharmaceutical company based in Liège, Wallonia region, Belgium, developing active specific immunotherapies using its Imotope™ technology platform. This approach targets severe chronic autoimmune diseases like type 1 diabetes and multiple sclerosis by inducing cytolytic CD4 T-cells to halt disease progression without impairing overall immune defense. The company secured €35 million ($39.5 million) in Series B financing and grants in 2019 to advance its clinical programs. Key investors include LSP, Epimède, SRIW, SFPI, and Noshaq, while Pfizer is a research collaborator for its rheumatoid arthritis Imotope™. Denis Bedoret was appointed CEO in September 2020. Imcyse was founded in 2010 as a spin-off from KU Leuven. Its business model centers on funded through venture capital equity rounds, grants, and research collaborations with pharmaceutical companies.
Imcyse has raised $64.6M across 2 funding rounds.
Imcyse has raised $64.6M in total across 2 funding rounds.
Imcyse has raised $64.6M in total across 2 funding rounds.
Imcyse's investors include Biogenosis, Epimede, KU Leuven, LSP, Noshaq, Pfizer, SFPI-FPIM, SRIW, Belfius, DGO6, Marc Moles le Bailly, Paul Van Dun.
Imcyse has raised $64.6M across 2 funding rounds. Most recently, it raised $25.8M Series B Extension in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 17, 2021 | $25.8M Series B Plus | — | Biogenosis, Epimede, KU Leuven, LSP, Noshaq, Pfizer, Sfpi Fpim, Sriw | Announced |
| Jun 18, 2019 | $38.8M Debt Financing | LSP | Belfius, Biogenosis, Dgo6, Marc Moles LE Bailly, Paul VAN DUN, Marc Foidart, Fontaine François, Franssen Christina | Announced |